Recent developments which may impact consumer access to, and demand for, pharmaceuticals: hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, June 13, 2001, Volume 4
U.S. G.P.O., 2001 - Medical - 235 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
180-day exclusivity agency ANDA Andrx's antihistamine antihistamine and antihistamine/decongestant approved drug benefit Bilirakis billion bioequivalence Biovail brand name drug broadcast advertisements Burr Cetirizine Chairman Citizen Petition Committee competition Congress Cosmetic Act cost court decision delay Delgado Downey Drug Administration drug applications drug manufacturer DTC advertising evaluated expired FDA's FDCA federal defendants filed Food and Drug Geiser Golenski hearing Hispanic ibuprofen impact IMS Health industry innovator drug issues labeling litigation loratadine medications medicines Michael Bilirakis neric Orange Book OTC status OTC switch over-the-counter status Pallone patent challenge patent listing percent pharmaceutical Pharmacy PhRMA physician pioneer prescription drug Prevention Magazine public health questions regulations regulatory risk Rx to OTC safe and effective safety side effects statement statutory Stupak Subcommittee submitted sumers testimony Thank therapeutically equivalent therapies Tiazac tion Waxman-Hatch Act WellPoint Woodcock Zyrtec